Publications by authors named "Victoria M Richon"

52Publications

CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.

Clin Cancer Res 2015 May;21(10):2198-200

Discovery and Preclinical Sciences, Sanofi Oncology, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2556DOI Listing
May 2015

Drug discovery in rare indications: opportunities and challenges.

Hematology Am Soc Hematol Educ Program 2013 ;2013:19-23

1Sanofi Oncology, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2013.1.19DOI Listing
December 2014

A687V EZH2 is a gain-of-function mutation found in lymphoma patients.

FEBS Lett 2012 Sep 28;586(19):3448-51. Epub 2012 Jul 28.

Epizyme, Inc., 325 Vassar St., Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2012.07.066DOI Listing
September 2012

The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.

FEBS Lett 2011 Oct 17;585(19):3011-4. Epub 2011 Aug 17.

Epizyme, Inc., 325 Vassar St., Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2011.08.018DOI Listing
October 2011

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

Cancer Cell 2011 Jul;20(1):66-78

Division of Hematology/Oncology, Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2011.06.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329803PMC
July 2011

Chemogenetic analysis of human protein methyltransferases.

Chem Biol Drug Des 2011 Aug 16;78(2):199-210. Epub 2011 Jun 16.

Epizyme, Inc., 840 Memorial Drive, Cambridge, MA 02139, USA Genstruct Inc., One Alewife Center, Cambridge, MA 02140, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1747-0285.2011.01135.xDOI Listing
August 2011

Targeting histone deacetylases: development of vorinostat for the treatment of cancer.

Epigenomics 2010 Jun;2(3):457-65

Epizyme, Inc., 840 Memorial Drive, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi.10.20DOI Listing
June 2010

Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.

Int J Toxicol 2010 Jan-Feb;29(1):3-19. Epub 2009 Nov 10.

Safety Assessment, Merck Research Laboratories, West Point, PA 19486, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1091581809352111
Publisher Site
http://dx.doi.org/10.1177/1091581809352111DOI Listing
March 2010

Protein methyltransferases as a target class for drug discovery.

Nat Rev Drug Discov 2009 Sep;8(9):724-32

Epizyme, Inc., 840 Memorial Drive, Cambridge, Massachussets 02139, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrd2974
Publisher Site
http://dx.doi.org/10.1038/nrd2974DOI Listing
September 2009

Development of vorinostat: current applications and future perspectives for cancer therapy.

Cancer Lett 2009 Aug 31;280(2):201-10. Epub 2009 Jan 31.

Merck Research Laboratories, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2009.01.002DOI Listing
August 2009

Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells.

Clin Cancer Res 2008 Sep;14(18):5735-42

Department of Cancer Biology and Therapeutics, Merck Research Laboratories, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-5074DOI Listing
September 2008

A new path to the cancer epigenome.

Nat Biotechnol 2008 Jun;26(6):655-6

Department of Cancer Biology and Therapeutics, Merck Research Laboratories, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt0608-655DOI Listing
June 2008

Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.

Clin Cancer Res 2007 Dec;13(24):7237-42

Merck Research Laboratories, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-2114DOI Listing
December 2007

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Mol Cancer Ther 2007 Jan 11;6(1):51-60. Epub 2007 Jan 11.

Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide, Hanson Institute, Adelaide, South Australia 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0144DOI Listing
January 2007

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.

Mol Cancer Ther 2006 Aug;5(8):1967-74

Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Box 066, 1515 Holcombe Boulevard, Houston, 77030, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-06
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-06-0022DOI Listing
August 2006

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.

Blood 2006 Aug 4;108(4):1174-82. Epub 2006 May 4.

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-09-008086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895868PMC
August 2006

Novel histone deacetylase inhibitors in the treatment of thyroid cancer.

Clin Cancer Res 2005 May;11(10):3958-65

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-03-0776DOI Listing
May 2005

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

J Clin Oncol 2005 Jun 16;23(17):3923-31. Epub 2005 May 16.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2005.14.167
Publisher Site
http://dx.doi.org/10.1200/JCO.2005.14.167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855284PMC
June 2005

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

Proc Natl Acad Sci U S A 2005 Mar 28;102(10):3697-702. Epub 2005 Feb 28.

The Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne 3002, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0500369102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC552783PMC
March 2005

Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.

J Immunol 2004 Sep;173(6):4171-8

Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University and Edward Via College of Osteopathic Medicine, Blacksburg, 24060, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.173.6.4171DOI Listing
September 2004

Histone deacetylase inhibitors.

Adv Cancer Res 2004 ;91:137-68

Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0065-230X(04)91004-4DOI Listing
November 2004

Histone deacetylase inhibitors: development as cancer therapy.

Novartis Found Symp 2004 ;259:269-81; discussion 281-8

Cell Biology Program, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, USA.

View Article

Download full-text PDF

Source
June 2004

Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo.

Methods Enzymol 2004 ;376:199-205

Discovery Biology, Aton Pharma, Inc., Tarrytown, New York 10591, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0076-6879(03)76013-3DOI Listing
July 2004

HDAC inhibitors for the treatment of cancer.

Curr Opin Investig Drugs 2003 Dec;4(12):1422-7

Aton Pharma Inc., 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA.

View Article

Download full-text PDF

Source
December 2003

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Proc Natl Acad Sci U S A 2004 Jan 26;101(2):540-5. Epub 2003 Dec 26.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.2536759100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC327183PMC
January 2004

Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.

Clin Cancer Res 2003 Nov;9(15):5749-55

Department of Pediatric Surgery, Sloan Kettering Institute and Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
November 2003

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Clin Cancer Res 2003 Sep;9(10 Pt 1):3578-88

Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan-Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
September 2003

Histone deacetylases.

Curr Opin Pharmacol 2003 Aug;3(4):344-51

Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1471-4892(03)00084-5DOI Listing
August 2003

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Proc Natl Acad Sci U S A 2003 Feb 7;100(4):2041-6. Epub 2003 Feb 7.

Medical and Molecular Genetics, Guy's, King's and St. Thomas' School of Medicine, King's College London, Eighth Floor Guy's Tower, Guy's Hospital, London SE1 9RT, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0437870100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC149955PMC
February 2003

Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

Blood 2003 May 16;101(10):4055-62. Epub 2003 Jan 16.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-11-3514DOI Listing
May 2003

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Proc Natl Acad Sci U S A 2002 Sep 20;99(18):11700-5. Epub 2002 Aug 20.

Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.182372299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC129332PMC
September 2002

Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

Anticancer Res 2002 May-Jun;22(3):1497-504

Div. Nutrition and Endocrinology, American Health Foundation, Valhalla, NY 10595, USA.

View Article

Download full-text PDF

Source
September 2002

Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.

Clin Cancer Res 2002 Mar;8(3):662-4

Aton Pharma, Inc., Tarrytown, New York 10591, USA.

View Article

Download full-text PDF

Source
March 2002